TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
CAMBRIDGE, Mass., Feb. 08, 2023 – TCR² Therapeutics Inc. (Nasdaq: TCRR) announced a management presentation at the SVB Securities Global Biopharma Conference (virtual) on February 14, 2023, at 1:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMBRIDGE, Mass., Feb. 08, 2023 – TCR² Therapeutics Inc. (Nasdaq: TCRR) announced a management presentation at the SVB Securities Global Biopharma Conference (virtual) on February 14, 2023, at 1:00 PM ET. This event will provide an update on the company’s progress in developing novel T cell therapies for solid tumors.
A live webcast is accessible via the company’s Investors page, with an archived replay available for 30 days post-presentation.
TCR² Therapeutics focuses on innovative T cell therapies, using their proprietary TRuC®-T cells to target and eliminate cancer cells effectively.
Details
News Market Reaction – TCRR
The recorded move for TCRR in the trading session of this news was -7.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
A live webcast of the presentation will be available on the Investors page of the Company’s website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.
About TCR² Therapeutics
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
Media Contact:
Kathy Vincent
kathy@kathyvincent.com
Investor Contact:
Eric Sullivan
Chief Financial Officer
eric.sullivan@tcr2.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.